Amgen Uses 454 in Search of New Biomarkers for Oncology Drug Response
April 27, 2010
Amgen Uses 454 in Search of New Biomarkers for Oncology Drug Response
In the study, Amgen researchers and academic collaborators used the Roche 454 Life Sciences platform to sequence nine genes in 320 tumor samples from a clinical trial of the EGFR inhibitor Vectibix. It represents one of the first applications of next-gen sequencing to characterize samples from a clinical trial.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- At AACR, Labs Report NGS-based Cancer Genotyping on FFPE Samples Concordant with MassArray Panels
April 4, 2012 / Clinical Sequencing News - U of Washington Debuts Targeted Sequencing Test for Mutations in Inherited Colon Cancer Genes
December 7, 2011 / Clinical Sequencing News - Illumina Sees Clinical Applications for MiSeq; Plans FDA Submission in 2012
August 3, 2011 / Clinical Sequencing News - IOM Workshop Discusses Interim Strategies to Handle Unresolved Challenges of Clinical Sequencing
July 27, 2011 / Clinical Sequencing News - Clinical Sequencing Papers of Note
July 27, 2011 / Clinical Sequencing News